All Updates

All Updates

icon
Filter
Partnerships
Aptamer Group partners with AstraZeneca to explore siRNA delivery methods for fibrotic liver cells
Precision Medicine
Jul 3, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Precision Medicine

Precision Medicine

Jul 3, 2024

Aptamer Group partners with AstraZeneca to explore siRNA delivery methods for fibrotic liver cells

Partnerships

  • Aptamer Group has partnered with AstraZeneca to develop a siRNA delivery vehicle for targeting fibrotic liver cells. Following the positive results from the study so far, this phase of this research will explore the potential of the non-viral delivery vehicle and its applicability with a tool siRNA.

  • Under the partnership, Aptamer will explore using its Optimer vehicles to deliver siRNAs provided by AstraZeneca to liver cells. If successful, this new development could improve current cell and tissue-targeting methods. This approach aligns with Aptamer's strategy to develop binders that can provide long-term value by addressing critical needs in the tissue-targeting area.

  • UK-based Aptamer Group specializes in developing and providing aptamer-based technologies, branded as Optimer binders. Due to their high affinity, specificity, and stability, these binders are utilized in research, diagnostics, and therapeutic applications. The company leverages its proprietary Optimer technology to create high-performance binders that can be applied in numerous biological processes and diagnostic tests. Its offerings include custom Optimer selection and development services to facilitate innovations in the life sciences sector.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.